If you need a #knee replacement move out of Ontario. More income disparity of access to #TKR in Ontario vs Pennsylvania. Lack of universal #healthcare in 🇨🇦. Oh Canada we fail. @RheumNow #ACR21 abst#1037 https://t.co/kobUlT3Ugr

Oral Calcitonin not recommended for OA - studies did not show efficacy Strontium Ranelate study below was considered a positive study in KOA with efficacy but had Cardiovascular toxicity - now off the market. https://t.co/gcYH9xoxeo

Cathepsin K - has some promise in Knee OA - now going to Phase 3 @RheumNow https://t.co/exUFqcCJy1

Marc Hochberg lecture at #ACR21 - Bisphosphonates limited and inconclusive data in radiographic progression of OA, some ⬇️ in bone marrow lesions! @RheumNow https://t.co/ciMUINBLwm

Dr. Marc Hochberg delivering the Oscar Gluck Memorial lecture - His talk titled "The Role of Bone in OA". He begins with this statement.... "DJD... Should never be used" - the rest of the lecture explains why. #ACR21 https://t.co/lYGsFu4Wpr https://t.co/IWP5J73mFO

• https://bit.ly/3kgPJ2l

MCP, wrist, elbow, shoulder and ankle: Not common sites for #osteoarthritis so consider a metabolic disease like CPPD🧐 @RheumNow #ACR21 #RheumTwitter #MedTwitter https://t.co/utId4ljsZK

Phase 3 observational extension study of Lorecivivint, intra-articular CLK/DYRK inhibitor that modulates Wnt and inflammatory pathways. Safety and tolerability. Efficacy at 6 and 12 month, but at 18month it disappeared @RheumNow #ACR21 abst#0729 https://t.co/9ycbVGKkmy

Single Intraarticular Canakinumab in Knee OA - 18-week randomized, double-blind, double-dummy Placebo and naproxen-controlled - effect no different than Placebo. Some efficacy in subgroup with high hsCRP. Need for subtypes in OA @rheumnow #ACR21 #abst0728 https://t.co/YlKTMf56wF